Search research articles
Contact Us
Filters
Showing results (151-160 of 255) with videos related to
Page
of 26
Sort By:
Psychiatric Services (Washington, D.C.)
|
May 3, 2008
What CATIE found: results from the schizophrenia trial
Marvin S Swartz, T Scott Stroup, Joseph P McEvoy, et al.
Schizophrenia Bulletin
|
July 18, 2013
Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis
Orwa Dandash, Alex Fornito, Jimmy Lee, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 10, 2018
Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
A S Atkins, A Khan, D Ulshen, et al.
JAMA Psychiatry
|
June 22, 2017
Placebo Response and Practice Effects in Schizophrenia Cognition Trials
Richard S E Keefe, Vicki G Davis, Philip D Harvey, et al.
The Lancet. Digital Health
|
December 18, 2020
A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial
Scott H Kollins, Denton J DeLoss, Elena Cañadas, et al.
Schizophrenia Research
|
May 14, 2014
The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore
Attilio Rapisarda, Michael Kraus, Yi Wen Tan, et al.
Schizophrenia Bulletin
|
October 2, 2013
Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories
James L Reilly, Kyle Frankovich, Scot Hill, et al.
Schizophrenia Bulletin
|
May 3, 2018
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
David Brown, Kazuyuki Nakagome, Joachim Cordes, et al.
The American Journal of Psychiatry
|
December 11, 2024
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials
William P Horan, Colin Sauder, Philip D Harvey, et al.
Innovations in Clinical Neuroscience
|
July 25, 2013
Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials
Richard S E Keefe, Helena C Kraemer, Robert S Epstein, et al.
Page
of 26
Search research articles
Search
Showing results (151-160 of 255) with videos related to
Sort By:
Page
of 26
Psychiatric Services (Washington, D.C.)
|
May 3, 2008
What CATIE found: results from the schizophrenia trial
Marvin S Swartz, T Scott Stroup, Joseph P McEvoy, et al.
Schizophrenia Bulletin
|
July 18, 2013
Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis
Orwa Dandash, Alex Fornito, Jimmy Lee, et al.
The Journal of Prevention of Alzheimer'S Disease
|
October 10, 2018
Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
A S Atkins, A Khan, D Ulshen, et al.
JAMA Psychiatry
|
June 22, 2017
Placebo Response and Practice Effects in Schizophrenia Cognition Trials
Richard S E Keefe, Vicki G Davis, Philip D Harvey, et al.
The Lancet. Digital Health
|
December 18, 2020
A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial
Scott H Kollins, Denton J DeLoss, Elena Cañadas, et al.
Schizophrenia Research
|
May 14, 2014
The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore
Attilio Rapisarda, Michael Kraus, Yi Wen Tan, et al.
Schizophrenia Bulletin
|
October 2, 2013
Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories
James L Reilly, Kyle Frankovich, Scot Hill, et al.
Schizophrenia Bulletin
|
May 3, 2018
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
David Brown, Kazuyuki Nakagome, Joachim Cordes, et al.
The American Journal of Psychiatry
|
December 11, 2024
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials
William P Horan, Colin Sauder, Philip D Harvey, et al.
Innovations in Clinical Neuroscience
|
July 25, 2013
Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials
Richard S E Keefe, Helena C Kraemer, Robert S Epstein, et al.
Page
of 26